Comments*

 
  • Media Relations

  • Researchers to Discuss Novel Treatments to Mitigate Cardiac Damage after Myocardial Infarction

    A conference at the New York Academy of Sciences on December 14 will feature sessions on new targets to improve tissue repair.

    Posted 12/11/2012

    NEW YORK, December 11, 2012—On Friday, December 14, researchers will convene at the Novel Therapeutic Targets in Myocardial Infarction conference (also available as a simulcast webinar) to discuss effective ways to minimize post-myocardial infarction (MI) cardiac remodeling through tissue repair and regeneration.

    Suffering an acute MI, better known as a heart attack, is a terrifying prospect. But the time period when the heart attack occurs is not the only danger zone. Patients that survive are at high risk of recurrent MIs and heart failure. In this context, identifying new targets to improve tissue repair—including preservation of the cardiac microvasculature, clearance of apoptotic cells, and tissue regeneration—may become of great interest to improve cardiac remodeling and function after MI.

    "Although current therapies for myocardial infarction are effective at restoring cardiac blood flow, they do not address the post-MI structural changes (i.e., cardiac remodeling) that diminish heart function and increase susceptibility to subsequent cardiac events," says conference organizer Mark Kaplan, PhD, Centers for Therapeutic Innovation, Pfizer Inc.

    "Recent discoveries have both advanced our understanding of the mechanisms that cause these structural changes and suggested a way to develop new medicines that prevent post-MI cardiac remodeling," adds Kaplan.

    This symposium brings together leading experts in the field to discuss the best strategy to prevent microvascular damage and improve tissue regeneration after MI, including:

                • Paddy Barrett, MD, Scripps Translational Science Institute;

                • Buddhadeb Dawn, MD, University of Kansas Medical Center;

                • Zahi A. Fayad, PhD, Mount Sinai School of Medicine;

                • Barbara Hempstead, MD, PhD, Weill Cornell Medical College;

                • Elizabeth McNally, MD, PhD, The University of Chicago Medicine;

                • Sharon Sokolowski, PhD, Pfizer Global R&D;

                • Filip Swirski, PhD, Massachusetts General Hospital and Harvard Medical School; and

                Edward Thorp, PhD, Northwestern University.  

     

    For more information, visit www.nyas.org/MyocardialInfarction.

    Media must RSVP to Diana Friedman (dfriedman@nyas.org; 212-298-8645).

    # # #

    About the New York Academy of Sciences
    The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With 25,000 members in 140 countries, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large. Please visit us online at www.nyas.org.

     

     

    EmailPrint